Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
AlloVir remains a top small-cap pick at Piper Sandler » 04:58
06/14/21
06/14
04:58
06/14/21
04:58
ALVR

AlloVir

$22.07 /

+0.21 (+0.96%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond keeps an Overweight rating on AlloVir with a $55 price target following meetings with management. The analyst sees "meaningful value-driving catalysts" by the end of 2021, with two proof of concept data events for Viralym-M, initial proof of concept data for ALVR109 in high-risk Covid-19 and the initiation of two pivotal Phase 3 trials. All programs remain on track, says Raymond, who continues to view AAlloVir as an "emerging leader" in virus specific cell therapies. The stock remains a top small-cap pick with an Overweight rating and $55 price target.

ShowHide Related Items >><<
ALVR AlloVir
$22.07 /

+0.21 (+0.96%)

ALVR AlloVir
$22.07 /

+0.21 (+0.96%)

03/25/21 Evercore ISI
Viracta Therapeutics initiated with an Outperform at Evercore ISI
03/22/21 Piper Sandler
AlloVir remains a top 2021 pick at Piper Sandler
02/11/21 Piper Sandler
AlloVir price target raised to $55 from $52 at Piper Sandler
08/24/20 Piper Sandler
AlloVir initiated with an Overweight at Piper Sandler
ALVR AlloVir
$22.07 /

+0.21 (+0.96%)

  • 30
    Jul
Conference/Events
AlloVir management to meet virtually with Piper Sandler » 11:46
06/11/21
06/11
11:46
06/11/21
11:46
ALVR

AlloVir

$21.57 /

-0.29 (-1.33%)

Virtual Meeting to be…

Virtual Meeting to be held on June 11 hosted by Piper Sandler.

ShowHide Related Items >><<
ALVR AlloVir
$21.57 /

-0.29 (-1.33%)

ALVR AlloVir
$21.57 /

-0.29 (-1.33%)

03/25/21 Evercore ISI
Viracta Therapeutics initiated with an Outperform at Evercore ISI
03/22/21 Piper Sandler
AlloVir remains a top 2021 pick at Piper Sandler
02/11/21 Piper Sandler
AlloVir price target raised to $55 from $52 at Piper Sandler
08/24/20 Piper Sandler
AlloVir initiated with an Overweight at Piper Sandler
ALVR AlloVir
$21.57 /

-0.29 (-1.33%)

  • 30
    Jul
Over a month ago
Earnings
AlloVir reports Q1 EPS (50c), consensus (40c) » 08:15
05/06/21
05/06
08:15
05/06/21
08:15
ALVR

AlloVir

$21.73 /

-1.85 (-7.85%)

As of March 31, AlloVir…

As of March 31, AlloVir had cash, cash equivalents, and marketable securities of $337M, which compares to cash, cash equivalents, and marketable securities of $356.3M as of December 31, 2020. "The first quarter of 2021 was one of significant progress for AlloVir and moved us closer towards our ambition to transform the lives of patients suffering from devastating and life-threatening viral diseases," said David Hallal, CEO and chairman of the board, AlloVir. "The appointment of Dr. Diana Brainard as our new CEO brings an unparalleled track record of success in building strong, durable global virology franchises, that have impacted the world, and I look forward to working with Diana and the team in my new role as Executive Chairman of the Board."

ShowHide Related Items >><<
ALVR AlloVir
$21.73 /

-1.85 (-7.85%)

ALVR AlloVir
$21.73 /

-1.85 (-7.85%)

03/25/21 Evercore ISI
Viracta Therapeutics initiated with an Outperform at Evercore ISI
03/22/21 Piper Sandler
AlloVir remains a top 2021 pick at Piper Sandler
02/11/21 Piper Sandler
AlloVir price target raised to $55 from $52 at Piper Sandler
08/24/20 Piper Sandler
AlloVir initiated with an Overweight at Piper Sandler
ALVR AlloVir
$21.73 /

-1.85 (-7.85%)

  • 30
    Jul
Over a quarter ago
Initiation
Viracta Therapeutics initiated with an Outperform at Evercore ISI » 08:07
03/25/21
03/25
08:07
03/25/21
08:07
VIRX

Viracta Therapeutics

$8.03 /

-0.11 (-1.35%)

, ATRA

Atara Biotherapeutics

$14.20 /

-0.66 (-4.44%)

, ALVR

AlloVir

$21.51 /

-1.725 (-7.42%)

, SNSS

Sunesis

$5.30 /

+ (+0.00%)

Evercore ISI analyst Josh…

Evercore ISI analyst Josh Schimmer initiated coverage of Viracta Therapeutics (VIRX) with an Outperform rating and $45 price target. The shares trades with a market cap of "only" about $300M, which Schimmer said is "far below" that of its closest comps, which he identifies as Atara Biotherapeutics (ATRA) and AlloVir (ALVR). Schimmer blames this on "limited investor awareness" following Viracta's recent reverse merger into Sunesis (SNSS). He argues that company's "highly efficacious and safe" regimen for EBV+ malignancies can meet "an important unmet need" and he models peak worldwide revenue of greater than $1B in 2028.

ShowHide Related Items >><<
VIRX Viracta Therapeutics
$8.03 /

-0.11 (-1.35%)

SNSS Sunesis
$5.30 /

+ (+0.00%)

ATRA Atara Biotherapeutics
$14.20 /

-0.66 (-4.44%)

ALVR AlloVir
$21.51 /

-1.725 (-7.42%)

VIRX Viracta Therapeutics
$8.03 /

-0.11 (-1.35%)

02/26/21 Oppenheimer
Viracta price target raised to $36 at Oppenheimer after Sunesis merger closing
ATRA Atara Biotherapeutics
$14.20 /

-0.66 (-4.44%)

03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
01/04/21 Roth Capital
Roth keeps Buy rating on Atara Biotherapeutics after filing delay
01/04/21 Roth Capital
Roth keeps Buy rating on Atara as initiation of BLA gets 'slightly' delayed
ALVR AlloVir
$21.51 /

-1.725 (-7.42%)

03/22/21 Piper Sandler
AlloVir remains a top 2021 pick at Piper Sandler
02/11/21 Piper Sandler
AlloVir price target raised to $55 from $52 at Piper Sandler
08/24/20 Piper Sandler
AlloVir initiated with an Overweight at Piper Sandler
08/24/20
Fly Intel: Top five analyst initiations
SNSS Sunesis
$5.30 /

+ (+0.00%)

02/23/21 Oppenheimer
Sunesis upgraded to Outperform at Oppenheimer
02/23/21 Oppenheimer
Sunesis upgraded to Outperform from Perform at Oppenheimer
06/24/20 Oppenheimer
Sunesis downgraded to Perform at Oppenheimer
SNSS Sunesis
$5.30 /

+ (+0.00%)

ATRA Atara Biotherapeutics
$14.20 /

-0.66 (-4.44%)

ALVR AlloVir
$21.51 /

-1.725 (-7.42%)

  • 09
    Dec
  • 29
    Jul
  • 30
    Jul
  • 27
    May
ATRA Atara Biotherapeutics
$14.20 /

-0.66 (-4.44%)

SNSS Sunesis
$5.30 /

+ (+0.00%)

Hot Stocks
AlloVir names Diana Brainard as new CEO » 16:01
03/22/21
03/22
16:01
03/22/21
16:01
ALVR

AlloVir

$25.58 /

+0.2 (+0.79%)

AlloVir announced that…

AlloVir announced that its board has appointed Diana M. Brainard, M.D., as the company's CEO, effective May 17, 2021. Dr. Brainard has served on AlloVir's Board of Directors since April 2019, initially as a Board Observer, and as an Independent Director since July 2020. Dr. Brainard currently serves as Senior Vice President and Head of the Virology Therapeutic Area at Gilead Sciences, Inc. She will succeed David Hallal, who will step down as CEO and continue to serve as Executive Chairman of the Board.

ShowHide Related Items >><<
ALVR AlloVir
$25.58 /

+0.2 (+0.79%)

ALVR AlloVir
$25.58 /

+0.2 (+0.79%)

03/22/21 Piper Sandler
AlloVir remains a top 2021 pick at Piper Sandler
02/11/21 Piper Sandler
AlloVir price target raised to $55 from $52 at Piper Sandler
08/24/20 Piper Sandler
AlloVir initiated with an Overweight at Piper Sandler
08/24/20
Fly Intel: Top five analyst initiations
ALVR AlloVir
$25.58 /

+0.2 (+0.79%)

  • 30
    Jul
Recommendations
AlloVir remains a top 2021 pick at Piper Sandler » 04:44
03/22/21
03/22
04:44
03/22/21
04:44
ALVR

AlloVir

$25.38 /

-0.87 (-3.31%)

After meeting with…

After meeting with management, Piper Sandler analyst Christopher Raymond says AlloVir remains a top 2021 pick with an Overweight rating and $55 price target. The analyst learned that all the company's programs remain on track for "multiple value-inflecting readouts this year." He continues to view AlloVir as an emerging leader in virus specific cell therapies.

ShowHide Related Items >><<
ALVR AlloVir
$25.38 /

-0.87 (-3.31%)

ALVR AlloVir
$25.38 /

-0.87 (-3.31%)

02/11/21 Piper Sandler
AlloVir price target raised to $55 from $52 at Piper Sandler
08/24/20 Piper Sandler
AlloVir initiated with an Overweight at Piper Sandler
08/24/20
Fly Intel: Top five analyst initiations
08/24/20 SVB Leerink
AlloVir initiated with an Outperform at SVB Leerink
ALVR AlloVir
$25.38 /

-0.87 (-3.31%)

  • 30
    Jul
Conference/Events
AlloVir management to meet virtually with Piper Sandler » 04:55
03/19/21
03/19
04:55
03/19/21
04:55
ALVR

AlloVir

$26.29 /

-1.5 (-5.40%)

Virtual Meetings to be…

Virtual Meetings to be held March 18-19 hosted by Piper Sandler.

ShowHide Related Items >><<
ALVR AlloVir
$26.29 /

-1.5 (-5.40%)

ALVR AlloVir
$26.29 /

-1.5 (-5.40%)

02/11/21 Piper Sandler
AlloVir price target raised to $55 from $52 at Piper Sandler
08/24/20 Piper Sandler
AlloVir initiated with an Overweight at Piper Sandler
08/24/20
Fly Intel: Top five analyst initiations
08/24/20 SVB Leerink
AlloVir initiated with an Outperform at SVB Leerink
ALVR AlloVir
$26.29 /

-1.5 (-5.40%)

  • 30
    Jul
Conference/Events
AlloVir management to meet virtually with Piper Sandler » 04:55
03/18/21
03/18
04:55
03/18/21
04:55
ALVR

AlloVir

$27.82 /

-0.82 (-2.86%)

Virtual Meetings to be…

Virtual Meetings to be held March 18-19 hosted by Piper Sandler.

ShowHide Related Items >><<
ALVR AlloVir
$27.82 /

-0.82 (-2.86%)

ALVR AlloVir
$27.82 /

-0.82 (-2.86%)

02/11/21 Piper Sandler
AlloVir price target raised to $55 from $52 at Piper Sandler
08/24/20 Piper Sandler
AlloVir initiated with an Overweight at Piper Sandler
08/24/20
Fly Intel: Top five analyst initiations
08/24/20 SVB Leerink
AlloVir initiated with an Outperform at SVB Leerink
ALVR AlloVir
$27.82 /

-0.82 (-2.86%)

  • 30
    Jul
Conference/Events
AlloVir management to meet virtually with Piper Sandler » 12:19
03/17/21
03/17
12:19
03/17/21
12:19
ALVR

AlloVir

$27.97 /

-0.67 (-2.34%)

Virtual Meetings to be…

Virtual Meetings to be held March 18-19 hosted by Piper Sandler.

ShowHide Related Items >><<
ALVR AlloVir
$27.97 /

-0.67 (-2.34%)

ALVR AlloVir
$27.97 /

-0.67 (-2.34%)

02/11/21 Piper Sandler
AlloVir price target raised to $55 from $52 at Piper Sandler
08/24/20 Piper Sandler
AlloVir initiated with an Overweight at Piper Sandler
08/24/20
Fly Intel: Top five analyst initiations
08/24/20 SVB Leerink
AlloVir initiated with an Outperform at SVB Leerink
ALVR AlloVir
$27.97 /

-0.67 (-2.34%)

  • 30
    Jul
Recommendations
AlloVir price target raised to $55 from $52 at Piper Sandler » 09:09
02/11/21
02/11
09:09
02/11/21
09:09
ALVR

AlloVir

$42.61 /

-1.26 (-2.87%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond raised the firm's price target on AlloVir to $55 from $52 and keeps an Overweight rating on the shares following the company's Q4 results. The setup for shares remains favorable with a "catalyst-rich 2021 on tap," Raymond tells investors in a research note. The analyst remains a buyer to levels now approaching$55 per share.

ShowHide Related Items >><<
ALVR AlloVir
$42.61 /

-1.26 (-2.87%)

ALVR AlloVir
$42.61 /

-1.26 (-2.87%)

08/24/20 Piper Sandler
AlloVir initiated with an Overweight at Piper Sandler
08/24/20
Fly Intel: Top five analyst initiations
08/24/20 SVB Leerink
AlloVir initiated with an Outperform at SVB Leerink
08/24/20 JPMorgan
AlloVir initiated with an Overweight at JPMorgan
ALVR AlloVir
$42.61 /

-1.26 (-2.87%)

  • 30
    Jul
ALVR AlloVir
$42.61 /

-1.26 (-2.87%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.